Last reviewed · How we verify

Bismuth quadruple therapy — Competitive Intelligence Brief

Bismuth quadruple therapy (Bismuth quadruple therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibacterial combination therapy. Area: Infectious Disease.

marketed Antibacterial combination therapy Helicobacter pylori Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Bismuth quadruple therapy (Bismuth quadruple therapy) — Zhongda Hospital.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bismuth quadruple therapy TARGET Bismuth quadruple therapy Zhongda Hospital marketed Antibacterial combination therapy Helicobacter pylori
Modified bismuth-containing eradication treatment Modified bismuth-containing eradication treatment Athens Medical Center marketed Antimicrobial combination therapy Helicobacter pylori cell wall and urease enzyme
metronidazole based quadriple therapy metronidazole based quadriple therapy mohamed bouchoucha marketed Antibiotic combination therapy Helicobacter pylori DNA and bacterial cell integrity
Amoxicillin-Clarithromycin-Lansoprazole Amoxicillin-Clarithromycin-Lansoprazole Fatma Zehra Arvas marketed Triple therapy antibiotic combination with proton pump inhibitor Helicobacter pylori bacterial ribosomes (amoxicillin and clarithromycin); H+/K+-ATPase (lansoprazole)
BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE The University of Texas Health Science Center, Houston marketed H. pylori eradication therapy (quadruple therapy) Helicobacter pylori (bacterial pathogen); omeprazole targets H+/K+-ATPase
PPI-amoxicillin-clarithromycin PPI-amoxicillin-clarithromycin National Taiwan University Hospital marketed Antibiotic combination therapy with acid suppression Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome
Bismuth-based susceptibility-guided treatment Bismuth-based susceptibility-guided treatment National Cheng-Kung University Hospital marketed Antimicrobial combination therapy (bismuth-based) Helicobacter pylori cell wall and bacterial proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibacterial combination therapy class)

  1. Zhongda Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bismuth quadruple therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/bismuth-quadruple-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: